NeuroHagana Overview
NeuroHagana (NH) develops an injectable emergency treatment for neurotrauma, irrespective of its type or severity. The novel treatment acts immediately to protect against the main factor in Neurotrauma pathology: Glutamate Excitotoxicity. NH’s technology has been pre-clinically validated in animal models of Spinal Cord Injury, Traumatic Brain Injury, and Athletes Concussion, with no side effects. The new treatment reduces the toxic impact of excessive Glutamate levels in the Central Nervous System, preventing irreversible neuronal damage and physical disabilities. First applications will be Spinal Cord Injury, first in Europe and USA. Other applications will be Traumatic Brain Injury and Stroke. Essential for paramedics, hospital trauma units, first aid teams and military forces, the new innovative drug aims to become a vital component of any core emergency kit, preventing permanent disabilities of the injured people and giving them the opportunity to regain their freedom.
Latest News
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | Undisclosed |
| Last funding | Undisclosed |
| Stage | Pre-Funding |
| Rounds | 0 |
| Investors | 0 |
Team Members
3
Employees: 1-10
Web & Social Links
| Website | www.neurohagana.com |
Locations
Tel Aviv-Yafo, Israel
Photos & Videos
2 item(s)
NeuroHagana Business
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & DevelopmentTarget Customer
Healthcare & Life SciencesHealthcareProvidersCore Technology
BiologicalsTags (6)
treatmentsneurosciencebiotechnologypharmaceuticalsneurologydisabilitiesGeographic Markets
EuropeNeuroHagana Financials
NeuroHagana Lifecycle
NeuroHagana News
1 articleNeuroHagana Team
Employee Info
| Employees (range) | 1-10 |
| Exact count | 5 |
| Team members | 4 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 7 classification IDs that could be used for matching.
NeuroHagana Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 80/100 |
| Missing | sector, funding rounds, markets, not claimed |
| BI Verification | Yanina Wainscheinker |
| Registrar ID | 516776986 |
| Phone | +972507752117 |
| Creator | Yanina Wainscheinker |
| Creator email | yanina.wainscheinker@sncentral.org |
| Last updater | Nitai Osem |
| Updater email | finder@sncentral.org |
| Last update | 2025-05-08T00:00:00.000Z |
| Created | 2024-11-07T00:00:00.000Z |
| Claimed | Yes |